These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1516042)

  • 1. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk.
    Colombo MP; Modesti A; Parmiani G; Forni G
    Cancer Res; 1992 Sep; 52(18):4853-7. PubMed ID: 1516042
    [No Abstract]   [Full Text] [Related]  

  • 2. T lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities.
    Kurt RA; Park JA; Panelli MC; Schluter SF; Marchalonis JJ; Carolus B; Akporiaye ET
    J Immunol; 1995 Apr; 154(8):3969-74. PubMed ID: 7706735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions.
    Stoppacciaro A; Forni G; Colombo MP
    Folia Biol (Praha); 1994; 40(1-2):89-99. PubMed ID: 7525363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
    J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escape mechanisms in tumor immunity: an update.
    Müller L; Kiessling R; Rees RC; Pawelec G
    J Environ Pathol Toxicol Oncol; 2002; 21(4):277-330. PubMed ID: 12510961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.
    Schmielau J; Finn OJ
    Cancer Res; 2001 Jun; 61(12):4756-60. PubMed ID: 11406548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local T helper cell signals by lymphocytes infiltrating intraocular tumors.
    Ksander BR; Acevedo J; Streilein JW
    J Immunol; 1992 Mar; 148(6):1955-63. PubMed ID: 1531848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine cross-talk between phagocytic cells and lymphocytes: relevance for differentiation/activation of phagocytic cells and regulation of adaptive immunity.
    Trinchieri G; Kubin M; Bellone G; Cassatella MA
    J Cell Biochem; 1993 Dec; 53(4):301-8. PubMed ID: 8300747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient inducation of local and systemic antitumor immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene.
    Cao X; Wang Q; Ju DW; Tao Q; Wang J
    J Exp Clin Cancer Res; 1999 Jun; 18(2):191-200. PubMed ID: 10464706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back.
    Walker PR; Saas P; Dietrich PY
    J Immunol; 1997 May; 158(10):4521-4. PubMed ID: 9144461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive cellular immunotherapy of cancer.
    Winter H; Fox BA
    Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
    [No Abstract]   [Full Text] [Related]  

  • 13. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
    Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP
    J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
    Chen PW; Ksander BR
    Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Propagation and characterization of lymphocytes from transplant biopsies.
    Duquesnoy RJ; Trager JD; Zeevi A
    Crit Rev Immunol; 1991; 10(6):455-80. PubMed ID: 1830745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expanding universe of regulatory T cell subsets in cancer.
    Gajewski TF
    Immunity; 2007 Aug; 27(2):185-7. PubMed ID: 17723212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes.
    Fox BA; Spiess PJ; Kasid A; Puri R; Mulé JJ; Weber JS; Rosenberg SA
    J Biol Response Mod; 1990 Oct; 9(5):499-511. PubMed ID: 2174966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for existence of oligoclonal tumor-infiltrating lymphocytes and predominant production of T helper 1/T cytotoxic 1 type cytokines in gastric and colorectal tumors.
    Matsutani T; Shiiba K; Yoshioka T; Tsuruta Y; Suzuki R; Ochi T; Itoh T; Musha H; Mizoi T; Sasaki I
    Int J Oncol; 2004 Jul; 25(1):133-41. PubMed ID: 15201998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The significance of Treg cells in defective tumor immunity.
    Kosmaczewska A; Ciszak L; Potoczek S; Frydecka I
    Arch Immunol Ther Exp (Warsz); 2008; 56(3):181-91. PubMed ID: 18512029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.